Spruce Biosciences (SPRB)
(Real Time Quote from BATS)
$0.47 USD
-0.01 (-1.88%)
Updated Aug 28, 2024 01:10 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Spruce Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 10 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 10 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 62 | 47 | 42 | 29 | 13 |
Income After Depreciation & Amortization | -52 | -47 | -42 | -29 | -13 |
Non-Operating Income | 5 | 2 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -48 | -46 | -42 | -30 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -48 | -46 | -42 | -30 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -48 | -46 | -42 | -30 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -53 | -47 | -42 | -29 | -13 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -52 | -47 | -42 | -29 | -13 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.51 | 23.53 | 23.36 | 5.99 | NA |
Diluted EPS Before Non-Recurring Items | -1.24 | -1.96 | -1.81 | -4.93 | NA |
Diluted Net EPS (GAAP) | -1.24 | -1.96 | -1.81 | -4.93 | NA |
Fiscal Year end for Spruce Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.61 | 2.00 | 2.89 | 3.07 | 2.17 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.61 | 2.00 | 2.89 | 3.07 | 2.17 |
SG&A, R&D, and Dept/Amort Expenses | 11.65 | 14.64 | 14.05 | 16.73 | 16.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.04 | -12.64 | -11.16 | -13.66 | -13.97 |
Non-Operating Income | 0.94 | 1.11 | 1.32 | 1.42 | 1.28 |
Interest Expense | 0.08 | 0.10 | 0.11 | 0.12 | 0.13 |
Pretax Income | -9.18 | -11.63 | -9.95 | -12.35 | -12.82 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.18 | -11.63 | -9.95 | -12.35 | -12.82 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.18 | -11.63 | -9.95 | -12.35 | -12.82 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 41.16 | 41.10 | 43.26 | 40.71 | 40.55 |
Diluted EPS Before Non-Recurring Items | -0.22 | -0.28 | -0.23 | -0.30 | -0.32 |
Diluted Net EPS (GAAP) | -0.22 | -0.28 | -0.22 | -0.30 | -0.32 |